Keros Therapeutics, Inc.
KROS
$11.58
$0.110.96%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | 3.55M | 651.00K | 271.00K | 234.00K | 151.00K |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 3.55M | 651.00K | 271.00K | 234.00K | 151.00K |
Cost of Revenue | 18.29M | 44.32M | 29.23M | 21.25M | 14.08M |
Gross Profit | -14.74M | -43.66M | -28.96M | -21.02M | -13.93M |
SG&A Expenses | 40.75M | 39.19M | 38.52M | 37.36M | 34.83M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 214.38M | 204.69M | 188.93M | 179.79M | 170.09M |
Operating Income | -210.83M | -204.03M | -188.66M | -179.56M | -169.94M |
Income Before Tax | -187.05M | -181.57M | -168.05M | -160.30M | -152.99M |
Income Tax Expenses | 300.00K | -- | -- | -- | -- |
Earnings from Continuing Operations | -187.35 | -181.57 | -168.05 | -160.30 | -152.99 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -187.35M | -181.57M | -168.05M | -160.30M | -152.99M |
EBIT | -210.83M | -204.03M | -188.66M | -179.56M | -169.94M |
EBITDA | -209.60M | -202.89M | -187.62M | -178.63M | -169.13M |
EPS Basic | -5.01 | -5.21 | -5.13 | -5.14 | -5.19 |
Normalized Basic EPS | -3.13 | -3.25 | -3.20 | -3.21 | -3.25 |
EPS Diluted | -6.42 | -6.62 | -6.46 | -6.47 | -6.52 |
Normalized Diluted EPS | -3.13 | -3.25 | -3.20 | -3.21 | -3.25 |
Average Basic Shares Outstanding | 149.72M | 139.51M | 131.58M | 125.08M | 117.77M |
Average Diluted Shares Outstanding | 149.72M | 139.51M | 131.58M | 125.08M | 117.77M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |